Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Patient-reported outcomes in several physical and mental health domains are poorer among users of traditional Chinese medicine (TCM), according to a study of Chinese American rheumatology patients. However, TCM may be used as an alternative for unmet therapeutic needs.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Ravulizumab is a potential treatment for paroxysmal nocturnal haemoglobinuria (PNH), with an efficacy and safety profile that persists over 52 weeks of follow-up, according to a new study presented at the recently concluded 61st Annual Meeting and Exposition of the American Society of Haematology (ASH 2019).
The combination of bevacizumab plus trabectedin (BT) shows promising clinical activity with limited toxicity in the treatment of women with partially platinum-sensitive ovarian cancer, according to the results of a phase II study. A regimen consisting of BT plus carboplatin also has good activity although with relatively increased toxicity.
Slideshow: Highlights from the 61st American Society of Hematology (ASH) Annual Meeting & Exposition.
Podcast: Dr Patrick Brown explains the advantages of blinatumomab over chemotherapy for first relapse of B-ALL in children and AYA.
Special Reports
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab
Fenofibrate 145 mg, simvastatin 20 mg FC tab
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Vonoprazan 10 mg and 20 mg FC tab
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Conference Reports
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Ravulizumab is a potential treatment for paroxysmal nocturnal haemoglobinuria (PNH), with an efficacy and safety profile that persists over 52 weeks of follow-up, according to a new study presented at the recently concluded 61st Annual Meeting and Exposition of the American Society of Haematology (ASH 2019).
Slideshow: Highlights from the 61st American Society of Hematology (ASH) Annual Meeting & Exposition.
Podcast: Dr Patrick Brown explains the advantages of blinatumomab over chemotherapy for first relapse of B-ALL in children and AYA.
Two phase II trials of once-daily concizumab injections for bleeding prophylaxis do not disappoint, with the drug shown to be both safe and effective in haemophilia A (HA) and haemophilia A/B with inhibitors (HAwI/HBwI).
The bi-specific T-cell engaging antibody blinatumomab bested chemotherapy as a post-reinduction consolidation prior to transplant in children and adolescents and young adults (AYAs) with first-relapse B-cell acute lymphoblastic leukaemia (B-ALL), according to phase III data presented at ASH 2019, highlighting the potential of blinatumomab as a new standard of care in this setting.
Treatment with the (ADP-ribose) polymerase (PARP) inhibitor olaparib led to a statistically significant and clinically meaningful improvement in radiological progression-free survival (rPFS) vs physician’s choice of new hormonal agent (NHA) enzalutamide or abiraterone + prednisone in men with advanced prostate cancer harbouring certain gene mutations that were identified through genetic testing, the PROfound* trial has shown.
Multimedia
